Amphetamine – Kodiac biolabs

Plain-language summaryIntrigue 75 / 100

Amphetamine is the prototype phenethylamine stimulant and the foundational compound for an entire pharmacological class. First synthesized in 1887 and developed clinically as Benzedrine in the 1930s, it works by reversing the transporters that normally pull dopamine, norepinephrine, and serotonin out of the synapse. Instead of inhibiting reuptake, it forces these neurotransmitters to flow outward, raising synaptic levels. Sold as Adderall (mixed salts), Dexedrine, and Evekeo for ADHD and narcolepsy. The two enantiomers behave differently: d-amphetamine is more dopaminergic and CNS-focused, l-amphetamine has stronger peripheral norepinephrine effects. Schedule II in the US with significant abuse potential. The canonical monoamine releaser in pharmacology research and a reference point for nearly every later phenethylamine. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

45/100

The canonical monoamine releaser reference standard, fully characterized and no longer a frontier target

Yeah, amphetamine is the original. First synthesized in 1887, Benzedrine by the 1930s, and by now there’s essentially a century of pharmacology that leaves the core mechanism completely mapped. VMAT2 reversal driving transporter-mediated efflux at DAT, NET, and to a lesser extent SERT, secondary TAAR1 agonism and MAO inhibition layered on top. Thats about as well-characterized as anything in small-molecule pharmacology. That completeness is the whole problem from a research-library standpoint.

What makes amphetamine useful in 2026 is almost entirely its role as a reference standard and positive control, not as a primary research target. Serious monoamine labs use it as the yardstick. That has real bench value, but it’s a different kind of value than we’re trying to surface in this library.

The TAAR1 angle deserves mention. Amphetamine is a TAAR1 agonist, and there’s genuine interest in parsing how much of its CNS effect runs through TAAR1 versus the classical transporter story. But here’s the thing: if you want to study TAAR1 biology, you’re better served by a selective TAAR1 agonist than by amphetamine, which is simultaneously hitting DAT, NET, VMAT2, MAO, and TAAR1. The pharmacological noise is baked in. For TAAR1-specific questions, this is the wrong probe.

Enantiomer pharmacology remains a modest active niche. The d-/l-split is well-documented, but mixed-salt formulations like Adderall keep generating clinical data that some groups mine for phenotype-specific questions around dopaminergic versus noradrenergic ratios. It’s incremental work, not paradigm-level inquiry.

Evidence quality and translational signal score high here because this is an approved drug with phase 3 trials, decades of mechanistic work in model systems, and a massive pharmacovigilance database. Those scores are real, but they reflect historical accumulation rather than active frontier energy. The compound works for ADHD and narcolepsy; no one disputes that.

Schedule II status is a practical ceiling on what most bench programs can actually do. Obtaining and maintaining a DEA Schedule II research exemption is non-trivial infrastructure. That’s not a scientific judgment on the compound, but it’s a real constraint for investigators who don’t already have the licensing in place.

We don’t think there’s much left to discover about amphetamine as a primary research target. The questions worth asking about monoamine releasers and TAAR1 biology are being answered with more selective tools. Amphetamine built the foundation. Its not the frontier.

Novelty: 12
Mechanism promise: 24
In-category differentiation: 42
Evidence quality: 78
Translational signal: 75
Research bench value: 62

Rationale Schedule II cap of 65 doesn’t bind because the raw score lands at 45 on its own merits. Novelty and mechanism scores are floored by a century of complete characterization; evidence and translational scores are high because it’s an approved drug, but those are the wrong axes for a research library that rewards frontier promise over known-quantity status.

Phenethylamine-class sympathomimetic monoamine-releasing agent with activity at the dopamine transporter, norepinephrine transporter, vesicular monoamine transporter 2, and trace amine-associated receptor 1

A racemic or enantiopure phenylpropylamine first synthesized in 1887, developed as the prototypical indirect sympathomimetic stimulant, and established as a first-line pharmacotherapy for attention-deficit/hyperactivity disorder and narcolepsy through potent reversal of monoamine transporter function and vesicular monoamine redistribution.

Abstract

Amphetamine (alpha-methylphenethylamine) is the prototypical phenethylamine-class sympathomimetic amine and the most extensively characterized indirect monoamine-releasing agent in clinical neuropharmacology. First synthesized by Lazar Edeleanu in 1887 at the University of Berlin and pharmacologically characterized by Gordon Alles in 1927, amphetamine entered clinical medicine in 1933 as the Benzedrine inhaler for nasal congestion and was subsequently developed for narcolepsy, depression, obesity, and, from the 1960s onward, attention-deficit/hyperactivity disorder (ADHD). The compound acts principally by reversing the direction of the plasma membrane dopamine transporter (DAT) and norepinephrine transporter (NET), producing non-exocytotic efflux of cytoplasmic dopamine and norepinephrine into the synaptic cleft; by inhibiting vesicular monoamine transporter 2 (VMAT2), redistributing vesicular monoamine stores into the cytosol; and by activating the intracellular trace amine-associated receptor 1 (TAAR1), which modulates transporter phosphorylation state and downstream signaling cascades. Secondary mechanisms include weak inhibition of monoamine oxidase and modest serotonin transporter (SERT) reversal at higher concentrations. The net pharmacological effect is a robust increase in synaptic dopamine and norepinephrine concentrations in the prefrontal cortex, striatum, and nucleus accumbens, producing the characteristic profile of enhanced attention, executive function, wakefulness, locomotor activation, and appetite suppression.

Pharmacokinetics are characterized by high oral bioavailability (approximately 75 to 100 percent depending on gastrointestinal pH and formulation), a plasma elimination half-life of approximately 10 hours for dextroamphetamine and 13 hours for levoamphetamine in adults, hepatic metabolism through cytochrome P450 2D6 (CYP2D6) hydroxylation and flavin-containing monooxygenase 3 (FMO3) N-oxidation, and pH-dependent renal excretion of unchanged drug. The two enantiomers exhibit differential potency: dextroamphetamine (the S-enantiomer) is approximately three to five times more potent than levoamphetamine (the R-enantiomer) at dopaminergic targets, while levoamphetamine retains relatively greater noradrenergic potency. Commercial formulations exploit this differential through racemic mixtures (mixed amphetamine salts), enantiopure dextroamphetamine preparations, and the prodrug lisdexamfetamine.

The clinical evidence base for amphetamine in ADHD is among the largest in psychopharmacology. The 2018 Lancet Psychiatry network meta-analysis of 133 randomized controlled trials encompassing over 10,000 adult participants identified amphetamines as the most efficacious pharmacotherapy for ADHD in adults, with standardized mean differences on core symptom scales exceeding those of methylphenidate, atomoxetine, modafinil, and bupropion. In children and adolescents, amphetamines demonstrated the largest effect sizes on clinician-rated symptom measures among all studied agents. The compound is additionally approved for narcolepsy type 1 and has been investigated in treatment-resistant depression, traumatic brain injury-related cognitive dysfunction, and obesity.

The safety profile at therapeutic doses is well characterized. Common adverse events include appetite suppression, insomnia, dry mouth, tachycardia, and modest systolic blood pressure elevation. Cardiovascular risk at therapeutic doses in individuals without structural heart disease is low, as demonstrated by multiple large pharmacoepidemiologic cohort studies. The principal long-term concern is the reinforcing properties of amphetamine mediated by mesolimbic dopamine signaling, which confer abuse liability; all amphetamine formulations carry a Schedule II controlled substance classification under the United States Controlled Substances Act. This monograph reviews the chemistry, stereochemistry, and synthesis of amphetamine; the multi-target molecular pharmacology including DAT, NET, VMAT2, and TAAR1 mechanisms; comprehensive pharmacokinetics; preclinical behavioral and neurochemical pharmacology; the clinical evidence base across ADHD, narcolepsy, and investigational indications; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety signals; and a comparative assessment of five alternative agents (methylphenidate, lisdexamfetamine, atomoxetine, modafinil, guanfacine) against amphetamine on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-378Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.